Abstracts

612 – Impact of Rapid Testing and Self-Administered Risk Questionnaires on Hepatitis C Screening Rates

Background Underdiagnosis remains a major barrier to Hepatitis C (HCV) elimination. The ATENEA study assesses whether the implementation of rapid testing combined with a self-administered risk assessment in Primary Care (PC) settings could enhance HCV detection. Methods This is a cluster-randomized, stepped-wedge trial (clinicaltrials.gov ID: NCT06528626) conducted across eight PC centers between July 2023 and…

890 – Network Bridges to Predict Emerging HIV Transmission Hotspots in North Carolina

Background Detecting recent and rapidly growing HIV transmission clusters is essential for timely public health intervention. Molecular epidemiology can detect people serving as network bridges, or connecting subclusters, who may be early indicators of cluster expansion. These connections often arise within slowly evolving, long-standing, genetically diverse clusters and may signal pathways of ongoing transmission. Methods…

944 – Partner Acquisition Rate by HIV Testing and Treatment Engagement: A Multicountry Analysis

Background Sexual partner acquisition rates are correlated with the speed with which HIV can transmit across a population through new partners. Understanding systematic differences in partner acquisition rates between those engaged in HIV testing and treatment can inform populations at greatest risk of transmission. Methods We analyzed Population-based HIV Impact Assessments (PHIAs), nationally representative household-based…

461 – A Humanized Microfluidics BBB Model With Recirculation for CNS ARV Distribution Evaluation

Background Antiretroviral (ARV) efficacy in the central nervous system (CNS) is hindered by poor penetration across the blood–brain barrier (BBB). Current in vitro BBB models are limited by non-human or immortalized cells, few relevant cell types, and static conditions that restrict pharmacokinetic/pharmacodynamic (PK/PD) sampling. We developed a microfluidic BBB model with primary human brain cells…

219 – Identification of Factors That Mediate Nuclear Retention of Intron-Containing HIV-1 Transcripts

Background HIV-1 replication depends on the Rev-mediated nuclear export of unspliced (US) and partially spliced (PS) viral RNAs through the CRM1 pathway. HIV-1 transcripts are generated from a single promoter, undergo extensive alternative splicing, and are highly enriched in adenosine nucleotides. While completely spliced (CS) viral RNAs are exported independently of Rev, the export of…

532 – Safety of Cabotegravir + Rilpivirine Long-Acting Regimen Among PLWH With Previous HBV Exposure

Background Cabotegravir + Rilpivirine long-acting regimen (CARLA) has no anti-HBV activity and is not recommended for PLWH with active HBV co-infection. No data exist on its hepatic safety among PLWH with resolved HepB (rHepB), especially among those with isolated HBcAb+ (IsHBcAb+).   Methods Retrospective multicenter observational study including PLWH on CARLA. Primary aim was to demonstrate hepatic…

554 – Third-Generation InSTI VH4524184 (VH-184) Has an Enhanced Resistance Profile vs Bictegravir

Background Integrase strand transfer inhibitors (INSTIs) are a cornerstone of HIV-1 treatment due to their potency, durability, and high barrier to resistance. Maintaining and improving these attributes are critical to meet the evolving needs of persons with HIV. VH4524184 (VH-184) is a third-generation INSTI with potential as a long-acting injectable that has demonstrated potent antiviral…